Stock listing

gettex:TEV Teva Pharmaceutical Industries Limited Aktie

German listing (gettex) of Teva Pharmaceutical Industries Limited · home listing TASE:TEVA

Follow Teva Pharmaceutical Industries Limited into a list and get an email when it puts out news.

Home listing price · TASE:TEVA

12,930 ILA (agorot) -10 (-0.1%)

Close on Oct 15, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TASE:TEVA

Since Jul 6, 2026 +21.9% · daily closes, Jul 6, 2026 – Oct 15, 2026, adjusted for splits
Day range
12,540 – 12,990 ILA (agorot)Oct 15, 2026
Volume
1.01M sharesOct 15, 2026
Teva Pharmaceutical Industries Limited logo
Ticker
gettex:TEV
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
gettex
Currency
EUR

What changed lately

Calls

Replays

  • Teva Pharmaceutical Industries (TASE:TEVA) Q2 2026 Earnings Call

    Wed, Jul 29, 2026 · 8:00 AM ET

    Watch Transcript

  • Teva Pharmaceutical Industries (TASE:TEVA) Q1 2026 Earnings Call

    Wed, Apr 29, 2026 · 8:00 AM ET

    Watch Transcript

  • Teva Pharmaceutical Industries (TASE:TEVA) Q4 2025 Earnings Call

    Wed, Jan 28, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

Oct 1, 2026

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Sep 28, 2026

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

Sep 23, 2026

Teva Releases Q3 2026 Aide Memoire

Sep 23, 2026

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Sep 14, 2026

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Sep 10, 2026

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Jun 18, 2026

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Jun 8, 2026

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Jun 5, 2026

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

Jun 4, 2026

All Teva Pharmaceutical Industries Limited news

Financings

  • Senior notes

    Sep 10, 2026

    Announced: about US$4.9B

    Use of proceeds: Redeem certain existing notes, pay related fees and expenses, and general corporate purposes including repaying outstanding debt

    Announced Sep 10, 2026

Read by 6ix AI from the company's releases

Decks

Teva Pharmaceutical Industries Limited on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
56 in the last 12 months · 100 in all · newest Oct 1, 2026 · oldest 2025
Calls
14 calls with a replay · 14 with a transcript · latest Jul 29, 2026
Decks
132 decks · latest Oct 9, 2026

Where Teva Pharmaceutical Industries Limited is listed

ListingExchangeCountryCurrency
TASE:TEVA · Home listingTASEIsraelILA
NYSE:TEVANYSEUnited StatesUSD
gettex:TEV · This pagegettexGermanyEUR
Frankfurt:TEVFrankfurtGermanyEUR
Tradegate:TEVTradegateGermanyEUR
BOATS:TEVABOATSUnited StatesUSD
OTC:TEVJFOTCUnited StatesUSD
LS Exchange:883035LS ExchangeGermanyEUR
B3:T1EV34B3BrazilBRL
BMV:TEVANBMVMexicoMXN
VIE:TEVAViennaAustriaEUR
BX Swiss:TEVBX SwissSwitzerlandCHF
LSIN:0LERLSINUnited KingdomUSD
Stuttgart:TEVStuttgartGermanyEUR
Hanover:TEVHanoverGermanyEUR
Lang & Schwarz:883035Lang & SchwarzGermanyEUR
BSESOF:TEVBSESOFBulgariaEUR
Dusseldorf:TEVDusseldorfGermanyEUR
Hamburg:TEVHamburgGermanyEUR
Munich:TEVMunichGermanyEUR

Log in to ask 6ix AI your own questions about Teva Pharmaceutical Industries Limited.